Roberto Mina

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Pieter Sonneveld, Meletios Α. Dimopoulos, Mario Boccadoro et al. · New England Journal of Medicine · 2023 · 435 citations · Full text

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival

Antonio Palumbo, Sara Bringhen, Alessandra Larocca et al. · Journal of Clinical Oncology · 2014 · 210 citations · Full text

Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients

Francesca Gay, Wilfried Roeloffzen, Meletios Α. Dimopoulos et al. · Blood · 2023 · 96 citations

Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma

Valeria Magarotto, Sara Bringhen, Massimo Offidani et al. · Blood · 2016 · 94 citations · Full text

Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study

Alessandra Larocca, Vittorio Montefusco, Sara Bringhen et al. · Blood · 2013 · 87 citations · Full text